MedTrace Logo

PET Imaging Using the Tracer [18F]VAT to Assess the Antidepressant Effect of Nicotine.

NCT07095205 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2025-07-31

No results posted yet for this study

Summary

In the brain, certain nerve cells communicate using a chemical called acetylcholine. Acetylcholine is thought to be important for several functions including mood, memory and wakefulness. The purpose of this study is to explore the role of these nerve cells in depression. Also, we would like to understand how nicotine, the study drug, works in depression and how it affects these nerve cells. To do this, brain imaging will be used before and after this treatment.

Conditions

  • Major Depressive Disorder (MDD)

Interventions

DRUG

Nicotine transdermal patch

The participants with MDD will receive Nicorette NicoDerm CQ nicotine transdermal patches for 8 days (7 mg/day for days 1-2, 14 mg/day for days 3-4, and 21 mg/day for days 5-8).

DRUG

PET Scan with [18F] VAT

All participants will undergo a PET scan at Baseline using tracer \[18F\] VAT. Participants with MDD will undergo a second post-treatment PET scan using tracer \[18F\] VAT.

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • Stony Brook University

    lead OTHER

Principal Investigators

  • Ramin Parsey, MD, PhD · Stony Brook University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-10-03
Primary Completion
2029-09-30
Completion
2029-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07095205 on ClinicalTrials.gov